Morgan Stanley
HSCS icon

Morgan Stanley’s Heart Test Laboratories HSCS Stock Holding History

Morgan Stanley’s Portfolio HSCS Stock Details HSCS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,290
Closed -$11.9K – 7970
2024
Q2 		$11.9K Buy
+2,290
New +$18.2K ﹤0.01% 6620
2022
Q4 		– Hold
0
– – – 7921
2022
Q3 		– Hold
0
– – – 7775

Other funds holding HSCS

HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
OLVIG
Oliver Lagore Vanvalin Investment Group Flint, Michigan $255M AUM
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley's HSCS Position: Q3 2024 in Review

Morgan Stanley sold out of Heart Test Laboratories (HSCS) in Q3 2024, closing a stake of 2,290 shares — an estimated $11.9K sold.

Morgan Stanley first reported a position in HSCS in Q2 2024 and held it in 1 quarter. The position peaked at $11.9K in Q2 2024. 6 funds tracked by Wall St. Rank hold HSCS as of Q3 2024.

  • Morgan Stanley reported no remaining Heart Test Laboratories position as of Q3 2024 after selling out during the quarter.
  • Morgan Stanley sold 2,290 Heart Test Laboratories shares in Q3 2024, an estimated $11.9K.
  • Morgan Stanley first reported a position in Heart Test Laboratories in Q2 2024 and held it in 1 quarter.
  • Morgan Stanley's Heart Test Laboratories position peaked at $11.9K in Q2 2024.
  • 6 funds tracked by Wall St. Rank held Heart Test Laboratories as of Q3 2024.

Based on Morgan Stanley's 13F filing for Q3 2024, filed 14 Nov 2024.